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Background: Recombinant tumor necrosis factor-a (TNF-a) combined to melphalan is clinically administered
through isolated limb perfusion (ILP) for regionally advanced soft tissue sarcomas of the limbs. In preclinical studies,
wild-type p53 gene is involved in the regulation of cytotoxic action of TNF-a and loss of p53 function contributes to the
resistance of tumour cells to TNF-a. The relationship between p53 status and response to TNF-a and melphalan in
patients undergoing ILP is unknown.
Patients and methods: We studied 110 cases of unresectable limbs sarcomas treated by ILP.
Immunohistochemistry was carried out using DO7mAb, which reacts with an antigenic determinant from the
N-terminal region of both the wild-type and mutant forms of the p53 protein, and PAb1620mAb, which reacts with the
1620 epitope characteristic of the wild-type native conformation of the p53 protein. The immunohistochemistry data
were then correlated with various clinical parameters.
Results: P53DO7 was found expressed at high levels in 28 patients, whereas PAb1620 was negative in 20. The tumours
with poor histological response to ILP with TNF-a and melphalan showed significantly higher levels of p53-mutated protein.
Conclusions: Our results might be a clue to a role of p53 protein status in TNF-a and melphalan response in clinical
use.
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introduction
Sarcomas are among the most resistant tumours to
chemotherapy (CT). In these tumours, preoperative
doxorubicin-based CT, at maximum tolerated drug doses, is
not very effective [40% of radiological response and 6% of
pathological complete response (CR)] [1] and does not
permit limb salvage in patients who needed an amputation
before CT [2].
Hyperthermic isolated limb perfusion (ILP) [3] combined
with tumour necrosis factor-a (TNF-a) and melphalan [4] is
currently one of the therapies available for patients with
advanced soft tissue sarcomas (STSs) of the limbs, allowing
conservative surgery. ILP requires isolation of the patients
involved limb, its connection to a heart–lung machine and the
administration of TNF-a and melphalan at 39–40C, followed
by conservative surgery 2 months later. The rationale is to
improve the response rate by increasing the drug concentration
while avoiding systemic toxicity. In a multicentre European
trial, ILP with high-dose TNF-a and melphalan resulted in
a 76% response rate and 71% limb salvage in patients with
limb-threatening STSs [5]. In a dose–response study [6],
objective tumour response (OR) (65%) and limb salvage (71%)
did not vary in the four different dose groups tested (TNF-a
dose between 0.5 and 4 mg). The well-studied mechanisms
involved in TNF-a activity are an early effect on tumour
vascularisation that is an increase in endothelium permeability,
leading to increased melphalan concentration within the
tissue tumour. The apoptosis pathway mediates a late effect
that induces a selective destruction of tumour vessels with
vascular occlusion due to intravascular coagulation followed











*Correspondence to: Dr J. Muret, Service d’Anesthe´sie, Institut Gustave-Roussy,
39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. Tel: +33 1 42 11 40 18;
Fax: +33 1 42 11 52 09; E-mail: muret@igr.fr
Both these authors contributed to this article on a par.
ª The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
p53 is a suppressor gene located on chromosome 17p13
and is mutated in 17% of soft tissue tumours [10] (IARC TP53
mutation database, R11 release, October 2006). Evidence has
been provided indicating that in sarcomas, p53 protein
mutation correlated with a worse outcome especially if
associated to an amplification of mdm2 gene [11]. In vitro
studies revealed that the tumour resistance to TNF-a-induced
cell death was associated with p53 gene mutation and the
subsequent loss of its transactivation activities [12, 13]. While
the disruption of wild-type p53 gene function by E6 gene
transfection protects MCF7 cells from TNF-a-induced
apoptosis, the adenovirus-mediated transfer of the wild-type
p53 gene sensitises TNF-a-resistant MCF7 cells to the cytotoxic
effects of this cytokine [14]. The mechanisms by which the
restoration of the wild-type p53 gene function in p53 gene
mutant cells increases their susceptibility to the cytotoxic
action of TNF-a include a restoration of caspase 8 cleavage
and the re-establishment of mitochondrial signs of apoptosis
[15]. This also correlated with a significant down-regulation
of c-myc and a decrease in retinoblastoma protein [16].
Moreover, melphalan, as an alkylating agent, induces cell
death through p53 that is activated by DNA damage [17, 18].
Mutated p53 may prevent from this activation and could
explain resistance of sarcomas to melphalan during ILP
treatment.
These findings indicate that p53 protein status may be an
important determinant of the efficacy of treatment protocols
on the basis of the use of apoptosis inducers such as TNF-a
and melphalan. In this context, wild-type p53 may be an
essential component in promoting the dynamic of cell death
and may help to achieve a significant therapeutic index of
cytotoxic mechanisms and develop more effective therapeutic
immune interventions.
These studies were designed to investigate whether
treatment response and clinical outcome of patients treated
with ILP were associated with p53 protein status. We
demonstrated that p53 protein mutation correlates with
histopathological response in patients with STS following ILP
treatment with TNF-a and melphalan.
patients and methods
Patients with unresectable STS of the lower or upper limb were treated
with ILP in the reporting centre. Cases undergoing such treatment in
our institution from June 2000 to June 2005 were included when
paraffin-embedded material of the tumour was available before (named
preoperative specimens) and/or after ILP at the time of the residual tumour
excision 2 months later (named postoperative specimens). All cases were
reviewed by a pathologist before treatment to ascertain diagnosis and to
verify the quality of the tissue samples submitted to the study. Our
institutional ethics committee approved the study.
hyperthermic ILP
Under general anaesthesia, the main artery and vein of the affected limb
were clamped and cannulated after heparinisation. Cannulae were then
connected to a heart–lung machine and a pneumatic tourniquet was
applied proximally to prevent leakage into the general circulation. ILP
consisted of extracorporeal circulation with mild hyperthermia (38–40C)
obtained with a heat exchanger. TNF-a (TNF-a-1a, Beromum,
Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) was injected
into the arterial line and 30 min later, 10-mg/l melphalan (Alkeran,
GlaxoSmithKline, London, UK) per limb volume was added for the
following 60 min. At the end of the procedure, a 4- to 6-l wash out of the
limb, using a mixture of Hartmann’s solution and macrodex, was carried
out. A delayed excision of the residual tumour was planned 2 months after
ILP excepted in the case of multiple tumours or metastatic progression.
The aim was to carry out en bloc residual tumour excision with free
margins whenever possible.
magnetic resonance imaging clinical response criteria
The clinical response was determined by magnetic resonance imaging
(MRI) carried out before and 2 months after ILP. The MRI examinations
included T1-weighted spin echo (SE) and fast SE T2-weighted fat-saturated
sequences, as well as dynamic sequences (T1-weighted SE repeated six
times every 40 s), displaying the maximum intensity slope in each pixel.
CR was defined by complete necrosis (>90%) of the tumour or
disappearance of all measurable disease. A partial response (PR) was
defined as a regression of the tumour size >50% in the product of the
bi-dimensional measurements. Stable disease (SD) was defined as no
change in the percentage of necrosis and in the tumour size. Progressive
disease (PD) was defined as a >25% disease progression or the
appearance of any new lesion. OR included CR and PR and nonresponse
(NR) included SD and PD.
histopathological response criteria
Histopathological response was defined as good if £10% identifiable
residual tumour cells were present in the postoperative specimens
obtained 8 weeks after ILP. If >10% residual tumour cells were
identifiable, histopathological response was defined as poor.
immunohistochemistry analysis
Blocks of tumour embedded in paraffin were analysed by a pathologist and
portions containing tumour were sectioned in freshly cut slides to carry out
immunohistochemistry following standard protocols using an automated
immunohistochemical processor [NexES IHC (Ventana, Tucson, AZ)].
The murine monoclonal primary antibodies were DO7 (M 7001, DAKO,
Glostrup, Denmark, 1 : 50, 20 min at 37C), which react with an epitope
which is localised in the amino-terminal region of both the wild-type and
mutant forms of the p53 protein [19], and PAb1620 (Ab-5, Calbiochem,
San Diego, CA, 1 : 320, overnight at 4C), which recognises the wild-type
native conformation of p53 protein [20]. After dewaxing, epitopes were
retrieved using a temperature-controlled water bath at 98C during 20 min
in sodium citrate buffer (pH 7.3, 10 mM Microm Microtech, Francheville,
France; Diapath, Bergamo, Italy, 30PA-0310) for DO7 and at 98C during
30 min in sodium citrate buffer (pH 6.0, Zymed, San Francisco, CA,
00-5000) for PAb1620. After cooling at room temperature, the following
steps were carried out according to the manufacturers’ instructions using
an iView DAB Detection Kit (Ventana) for DO7, and an ABC avidin–biotin
kit (VECTASTAIN ABC, Vector Laboratories, Burlingame, CA, PK-6200)
for PAb1620. For DO7, diamino benzidine (Ventana for DO7 and NovaRed
vector, SK-4800 for PAb1620) was used as chromogen with haematoxylin
(Hemalun, Mayer, RAL reactives, Martillac, France) as counter stain.
Positive controls for DO7 mAb included sections from a breast cancer
showing genetically proven missense mutation of the p53 gene (Figure 1A)
and for PAb1620, paraffin-embedded MCF-7 cell pellets derived from
a breast adenocarcinoma including an accumulation of wild-type p53
protein (Figure 1B). Negative controls included sections from another
breast tumour with a nonsense p53 mutation. Controls were included in
each analysis with DO7 and PAb1620. PAb1620 antibody was used in those
samples positive for DO7. The incubation conditions for PAb1620 were
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adjusted so that it reacted with MCF-7 cells, but not with the p53-mutated
tumour cells.
analysis of immunostaining
Two pathologists blindly evaluated specimens for p53 staining with DO7
and PAb1620. The percentage of positive cells was recorded and used to
attribute a score on a scale 0–3 as follows: score 0 if <10% cells were
positive; score 1 if 11%–25% of cells were positive; score 2, 26%–50%
positive cells and score 3, >50% positive cells [21]. If the score was 2 or 3,
samples were considered as positive for the antibody tested and negative
under 2. Samples were considered to be mutated for p53 protein when they
reacted with DO7, but not PAb1620. If a discordance was observed for
p53 status between pre- and postoperative specimens in patients with
both specimens available, p53 was considered to be mutated.
statistical design
Results are expressed as percentages or medians and ranges. Survival and
disease-free survival (first recurrence to occur, i.e. metastases, second
cancer, local relapse and death) were calculated using the Kaplan–Meier
method [22] and Rothman’s 95% confidence intervals (95% CIs) [23].
Survival curves were compared using the log-rank test [24].
results
patient characteristics
One hundred and six consecutive patients with a locally
unresectable limb STS were treated by ILP and included in this
study. Clinical characteristics of the patients are represented in
Table 1. Four patients with a locally unresectable desmoid
tumour were also treated by ILP and included in this study.
Tumour concerned superior limb in 37% of patients and
inferior limb in 63%. Size of the tumour was 50 and 80 mm,
respectively. Histopathological subtypes are liposarcoma
(n = 24, 22%), synovial sarcoma (n = 24, 22%),
undifferentiated sarcoma (n = 19, 17%), malignant
peripheral nerve sheath tumours (n = 13, 12%), epithelioid
sarcoma (n = 9, 8%), leiomyosarcoma (n = 5, 5%),
fibroblastic sarcoma (n = 3, 3%), desmoids tumours
(n = 4, 4%), angiosarcoma (n = 3, 3%) and other (n = 6).
Before ILP, 30 patients (27%) had been treated with
radiotherapy, 56 (51%) by CT, 1 had a previous ILP and
63 had undergone surgery (37 once, 11 twice, 15 three to nine).
tumour response and post-ILP evolution
Complete clinical response evaluated by MRI reached 45%
and overall response 70%. Good histopathological response
to ILP treatment was found up to 33% (Table 2).
Limb salvage was initially achieved in 90% of our patient
population but this fell to 82% at a median time of 19 months
after ILP.
By 1st December 2005, 66 patients of the 110 were still being
followed, whereas follow-up was lost for 18 patients (16 had
been followed until 2004 and 2 until 2003). In all, 26 (24%)
patients had died. Of the patients in this study, nine had
metastasis before treatment, seven of who died. In the
remaining 101 patients, 18 patients (18%) had local recurrence
[at a median time of 12 months (2.5–30)] and 30 (30%) had
Table 1. Clinical characteristics of the patients before ILP
No. and % Median (range)
Male/female 58/52
Age (years) 45 (8–81)
Location and size
Superior limb size (mm) 41 (37%) 50 (10–200)











Synchronous metastasis 9 (8%)
aIn 100 patients, histological grade could not be retrieved in 10 patients
because initial histological diagnosis was made years before.
ILP, isolated limb perfusion.
Figure 1. Immunohistochemical positive controls: sections of a breast
cancer showing genetically proven missense mutation of the p53 gene were
used as a positive control for DO7 (A) and paraffin-embedded MCF-7 cell
pellets deriving from a breast adenocarcinoma cell line including an
accumulation of wild-type p53 protein were used as a positive control for
PAb1620 (B).
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metastasis [at a median time of 10 months (2–40)], 10 had both
and 2 deceased during follow-up without metastasis or
recurrence.
After ILP (and eventually residual tumour excision),
57 patients (52%) received adjuvant therapy consisting of
radiotherapy in 48 patients, systemic CT in 3 patients and
a combination of both in 6 patients. In 40 patients (36%),
surgery was the sole treatment after ILP.
p53 protein status
We analysed a total of 170 slides belonging to 110 different
patients. Sixty patients had both pre- and postoperative
specimens, 35 had preoperative specimens only and 15 had
postoperative specimens only. Among the 35 patients without
postoperative specimens, no residual tumour was found after
ILP in 13, and 13 patients (12%) were not operated on after ILP
(six for multiple tumour and seven for metastatic progression).
Three patients were amputated outside our institution and
specimens could not be retrieved. Six patients had surgery
but histochemistry could not be carried out due to lack of
tumour material. All the 15 patients without preoperative
specimens had been treated before ILP in other hospitals and
this material could not be retrieved.
Ninety-five preoperative specimens and 75 postoperative
specimens were immunostained with p53 DO7 mAb. p53
protein was overexpressed in 39, which were immunostained
with PAb1620 mAb (Figure 2). Afterwards, 10 preoperative
specimens and 14 postoperative specimens were p53 DO7
accumulated and PAb1620 negative corresponding to
20 patients with a mutated p53 protein. Among the
60 patients with both pre- and postoperative specimens
available, we did not find the same result before and after ILP
in nine (Table 3).
Patients’ tumour characteristics in relation to p53 protein
mutation are represented in Table 2.
p53 protein mutation and clinicopathological
implications
As depicted in Figure 3, tumours of patients with poor
histological response to ILP with TNF-a showed significantly
higher levels of mutated p53 protein as 94% of patients with
mutated p53 protein had a poor histopathological response.
We, however, found a lack of correlation between mutated p53
protein and survival (Figure 4), disease-free survival (Figure 5)
or MRI response. No correlation was observed between
histopathological response and disease-free survival either (data
not shown, P = 0.65).
With a median follow-up of 25 months, the 2-year overall
survival rates (95% CI) were 88% (78%–93%) and 69%
(43%–86%) in the p53 wild-type and mutated p53 protein
groups (P = 0.1) (Figure 4). The 2-year disease-free survival
rates were 62% (50%–73%) and 40% (19%–65%), respectively,
(P = 0.31) (Figure 5).
discussion
In the course of these studies, we examined the
immunohistochemical expression of p53 in STS patients and
analysed correlations between the immunohistochemical
findings and treatment response following ILP with TNF-a and
melphalan.
Our current results by immunohistochemical detection of
mutated p53 protein with two different antibodies support the
notion that mutated p53 protein significantly correlates with
poor histopathological response. A better control of the disease,
at least by histopathological examination, may be due to
a better sensitivity of tumour cells to TNF-a and melphalan
when p53 protein is wild type. Since we had no control
group (i.e. not treated with TNF-a and melphalan), we
cannot make any final statement regarding this hypothesis.
Preclinical studies on cell lines, however, indicate the role of
p53 gene mutation in tumour response to TNF-a since
transfection of wild-type p53 gene in cell lines with mutant
p53 gene sensitises cells to the cytotoxic effect of TNF-a [16].
Moreover, melphalan can be discussed as another aspect of
drug resistance. It has been established that STSs do not
respond to melphalan alone even in the context of ILP.
It was demonstrated experimentally [25, 26] that TNF-a
selectively increases melphalan penetration in tumour tissue
and we postulate that it is the case in this clinical setting.
STS are not necessarily resistant to melphalan, but rather
there is a lack of drug penetration in the tumour in the
absence of TNF-a. ILP uses two compounds that are
synergistic but do not hit the same target. TNF-a has an
early effect on tumour vascularisation that increases
permeability. The late effect is to induce a strong apoptosis of
Table 2. Responses to ILP according to p53 protein mutation





0.5 mg 18 15 3
1 mg 53 46 7
2 mg 20 13 7
3 mg 11 9 2
4 mg 8 7 1
MRI response
CR 50 (45%) 43 7
PR 27 (25%) 18 9
OR 77 (70%) 61 16
NR 32 (29%) 29 3
Histopathological responsea
Good 32 (33%) 31 1
Poor 64 (67%) 47 17
Post-ILP surgery
No surgery 13 (12%) 11 2
Conservative surgery 86 (78%) 69 17
Initial amputation 11 (10%) 10 1
Local recurrenceb 18 (18%) 15 3
Metastatic recurrenceb 30 (30%) 22 8
aIn 96 patients, histopathological response was not carried out in 13
patients who were not operated on and in one patient amputated outside
our institution.
bIn 101 patients, 9 patients had a synchronous metastasis at the time of ILP.
TNF-a, tumour necrosis factor-a; MRI, magnetic resonance imaging; CR,
complete response, PR, partial response; OR, Objective tumour response;
NR, nonresponse; ILP, isolated limb perfusion.
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endothelial cells and the collapses of the tumour vessels. In
contrast, as an alkylating agent, melphalan induces cell death
through p53 that is activated by DNA damage [17, 18]. In our
study, we observed an increased accumulation of p53 protein in
tumours that did not respond histologically to ILP. p53
protein-increased expression indicates p53 mutation and
inactive protein accumulation. In other words, sarcomas that
did not respond histologically to ILP may be resistant to TNF-a
and also to melphalan because of the lack of p53 activation.
Our patients’ population of 110 included 14 different
histological subgroups of STS and different types of
pretreatment (surgery, radiotherapy, CT and combinations).
STS are very uncommon tumours, and in studies with STS
patients treated by ILP, it was previously demonstrated that
despite different histological subgroups are characterised by
Table 3. Immunochemistry data using D07 and PAb1620mAb in the 60
patients with both pre-and postoperative specimens available
Patients (n) p53 DO7 expression and
negative PAb1620 staining in
the preoperative specimens





























Wild type p53 protein 
*
Figure 3. Correlation between mutated p53 protein and poor
histopathological response; * P = 0.005 (Fisher).
Figure 2. Immunohistochemical analysis of p53 (DO7, detecting both wild-type and mutant forms of p53 protein and PAb1620 detecting only wild-type
p53 protein) in a sarcoma with p53 protein mutation (A and B) showing (A) nuclear immunostaining for DO7 and (B) negative staining for PAb1620 and
in a sarcoma with nonmutational accumulation of wild-type p53 protein (C and D) showing (C) nuclear immunostaining for DO7 and (D) for PAb1620.
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different molecular backgrounds, TNF-a response in ILP
treatment was independent of the type of STS [5, 6, 27].
Moreover, overall response to TNF-a and melphalan did not
differ significantly according to pre-irradiation, preoperative
CT and TNF-a doses [6, 28].
Although a good correlation (73%) between radiological and
histopathological responses was observed in our study, no
significant correlation between mutated p53 protein and
clinical tumour response assessed by radiology was found as
we found for histopathological response. This discordance may
be attributable to the fact that a notable discrepancy exists
between the clinical and the histopathological response
assessment in ILP studies. The clinical evaluation of tumour
regression is on the basis of the estimated size of the necrosis
of the tumour, which is measured 2 months after ILP and
can be operator dependant. The histopathological response,
i.e. assessment of the percentage of viable cells, can be difficult
to evaluate because it is on the basis of the residual volume
of the tumour. If the tumour shrinks but still contains viable
tumour cells, the percentage of residual tumour is often
overestimated. Our series shows a higher rate of clinical CR
(45%) than other series [9]. This may be due to the fact that
we did not combine clinical and histopathological response
to define the final outcome [5]. CR per se, however, is not
crucial, whether the tumour responds completely or partially
is irrelevant, as long as it becomes amenable to residual tumour
excision without loss of limb function. Our overall response
rate (70%) was not different from other studies [9, 27].
Contrary to other studies [11, 29], we did not find any
correlation between p53 protein mutation and survival or
disease-free survival. Interestingly, in Cordon-Cardos et al. [11]
study, the presence or absence in tumour cells of p53 protein in
high levels as measured by immunohistochemistry was a very
good indicator of patient survival. Treatment modalities,
however, were not specified and patients had apparently less
locally advanced sarcomas. It should be noted that our results
were obtained in a selected group of patients with very
extensive disease. All had a locally advanced tumour considered
as unresectable and were candidates for amputation. Nine
patients of our series had already distant metastasis. The
majority of the tumours were high grade (84%) and with a high
number of recurrences before ILP [53 patients (48%) had at
least one recurrence and 14 patients (13%) had >2]. In this
rather restricted group of patients with very bad prognoses,
survival rates are difficult to analyse if compared with other
studies on sarcoma with all types of patients (low grade,
absence of recurrence etc.).
We did not study p53 gene status mutation in our patients’
tumours but we searched for p53 protein mutation by
immunohistochemistry. In the case of missense gene
mutation, mutant p53 gene product is characterised by
a conformational change of the protein with subsequent
prolonged half-life and stability. The accumulated mutant
protein is therefore detectable by immunohistochemistry, and
immunostaining of tissue sections may be an important
surrogate for p53 genetic analysis [30–32]. In nonsense p53
gene mutations, products however, are truncated proteins and
are undectable by immunohistochemistry. In our experience
with carcinomas of the head and neck with p53 gene
sequencing, a good correlation was found between tumours
harbouring missense mutations and p53 DO7 mAb detection
[33]. Moreover, use of DO7 mAb with antigen retrieval was
found to be the most sensitive and specific procedure for
assessing p53 protein mutations [34]. In our study, 28 of 110
patients were p53 DO7 accumulated (25.4%). In Cordon-
Cardo et al. [11] study, 56 of 211 sarcomas had an
overexpression of p53 (26.5%). In his study, in the last analysis
with DNA sequencing carried out on 73 tumours, the
overexpression of p53 protein correlated with missense
mutations characterised by a conformational change of the
protein. The majority of p53 gene mutations are missense (78%
in germ line mutations and 74% in somatic mutations) [10]
(IARC TP53 mutation database, R11 release, October 2006)
and among sarcoma, 69% of the p53 mutations are missense,
13.4% are silent and 6.06% nonsense [10] (IARC TP53
mutation database, R11 release, October 2006). We, however,
could not even do the RT–PCR technique procedure because
we did not have any frozen material. In fact, in the
postoperative specimens, it was not possible to do the sections
for freezing because it was not possible to distinguish the
tumour areas.
Moreover, the presence of p53 protein accumulation may
be the result of a nonmutational stabilisation of this protein
which binds to viral (adenovirus) or cellular (mdm2)
oncoproteins [11]. In our study, considering to discriminate
p53 protein accumulation with and without any p53 gene
mutation, we used the PAb1620 antibody which recognises
Mutated p53 protein
Wild-type p53 protein 
90 64 49 23 7 1







0 1 2 3 4 5 6 years
at risk
Figure 4. Survival according to p53 protein mutation; P = 0.10 (log-rank).
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84 44 29 13 2
17 9 5 2at risk
Figure 5. Disease-free survival according to p53 protein mutation;
P = 0.31 (log-rank).
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the 1620 epitope present only in the wild-type p53 protein.
Out of 39 specimens expressing p53 DO7, 24 did not express
1620 epitope corresponding to 20 patients (18.2%).
Prevalence of p53 gene mutation in soft tissue tumour is
17.2% [10].
The data of the present studies also emphasise that among
the 60 patients with both pre- and postoperative specimens
available, in nine patients, p53 protein status was different.
In five cases, we found p53 protein to be mutated in
postoperative but not in the preoperative specimens. This
discordance may be explained by the fact that the biopsy was
carried out in some cases at the beginning of the disease and
the tumour may have modified its p53 gene status after
systemic chemotherapies performance [35]. Moreover,
cytotoxic treatment leads to a significant reduction in the
number of tumour cells that are sensitive to the therapy.
Tumours that survive the treatment are enriched in resistant
clones and are likely to display the p53 status associated
with chemoresistance. In four other cases, p53 protein was
mutated in the pre- but not postoperative specimens. This
may be due to the fact that a different tumour clone was
selected in the pre- and postoperative specimens.
In addition, as it is known that therapy-caused events in
the context of ILP occur timely close to the treatment event
[36], the p53 status detected 2 months following ILP may
represent the late outcome, resulting not only from the
direct effect of the therapy but also from several events such
as inflammation and hypoxia. It is, however, not possible
for ethical reasons to obtain samples from these patients
before the residual tumour excision carried out 2 months
after ILP.
p53 status may influence histological response to ILP
treatment. If this result is confirmed in a largest study,
it may play a role in TNF-a response in clinical use: it could
help us to decide on postoperative treatments after ILP.
Patients with mutated p53 protein could benefit from a more
aggressive treatment including postoperative radiotherapy and
further CT. Radiotherapy post-ILP improves local tumour
control in limb-saving treatment of STS even after radical
resection [37]. The decision of its use in this combined
modality treatment might be difficult to take since adjuvant
irradiation may result in acute and late morbidity such as worse
limb strength, oedema and delayed pathologic fractures with
pseudarthrosis which are difficult to treat. In patients for
whom the decision is difficult to take, we suggest analysing
p53 status because a mutated p53 may tend to have a high
risk of histological NR. Moreover, in the future, manipulation
of p53 status may improve effectiveness of ILP treatment
and the clinical use of compounds [38] able to restore p53
function or p53 gene transfer [39] could be a novel strategy
for optimising the efficiency of TNF-a in human cancer
treatment.
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